Omnicell (NASDAQ:OMCL) PT Raised to $41.00 at Wells Fargo & Company

Omnicell (NASDAQ:OMCL) had its price target hoisted by Wells Fargo & Company from $30.00 to $41.00 in a research report report published on Monday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other equities research analysts also recently issued reports about the company. Benchmark reaffirmed a buy rating and issued a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the stock a neutral rating in a research report on Friday, August 23rd. Barclays raised Omnicell from an underweight rating to an equal weight rating and lifted their target price for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Bank of America lifted their target price on Omnicell from $34.00 to $44.00 and gave the stock a buy rating in a research report on Friday, August 2nd. Finally, StockNews.com raised Omnicell from a hold rating to a buy rating in a research report on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $41.33.

Omnicell Trading Up 0.3 %

Shares of NASDAQ:OMCL opened at $42.73 on Monday. The company has a market cap of $1.96 billion, a P/E ratio of -92.89, a P/E/G ratio of 47.35 and a beta of 0.83. The stock’s 50-day moving average is $43.10 and its 200-day moving average is $33.95. Omnicell has a 52-week low of $25.12 and a 52-week high of $45.84. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm’s revenue was down 7.4% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. Equities research analysts predict that Omnicell will post 0.64 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its holdings in Omnicell by 23.1% during the third quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after purchasing an additional 2,188 shares in the last quarter. Diversified Trust Co raised its stake in shares of Omnicell by 43.0% in the third quarter. Diversified Trust Co now owns 21,966 shares of the company’s stock valued at $958,000 after acquiring an additional 6,602 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Omnicell by 67.3% in the third quarter. SG Americas Securities LLC now owns 25,157 shares of the company’s stock valued at $1,097,000 after acquiring an additional 10,116 shares during the last quarter. Finally, Algert Global LLC raised its stake in shares of Omnicell by 9.8% in the second quarter. Algert Global LLC now owns 51,942 shares of the company’s stock valued at $1,406,000 after acquiring an additional 4,617 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.